SCIENCE DRIVEN BY A HIGHLY VALIDATED TARGET
The Parkin protein is established as the critical mediator of mitochondrial health. FinsnoBio has built a technology platform that is designed to leverage our depth of expertise in small molecule modulation of the Parkin enzyme—a molecule with proven ability to respond to, and remove damaged mitochondria. Removing damaged mitochondria eliminates multiple signals from the cellular stress response.
Parkin-Dependent Mitophagy
Parkin is a highly validated E3 ubiquitin ligase with demonstrated therapeutic potential in neurology and oncology. At FinsnoBio we have dedicated our careers to studying E3 ligases and have developed a robust paradigm in order to overcome the challenges that historically prevented E3 ligase therapeutic advancement into the clinic.
Our lead molecules are designed from hits identified in a rational pharmacophore screen based on computational analysis of the Parkin crystal structure. We are also actively identifying additional chemical matter through deployment of new structure-based technologies. Our prowess in demonstrating Parkin’s transition from an inactive state to an active state provides proprietary structural starting points for new compounds.
Our vision is to revive the power of the mitochondria through the development of safe and effective therapeutics.
E3 Ligase Enzymes
E3 ligase enzymes like Parkin act to destroy specific proteins at specific times in specific places, thus they are the key mediator for directing cellular fate. E3 ligases chemically add a ubiquitin modification to substrates, and this modification signals cellular machinery to degrade the substrate. Small molecules that can control the activity of E3 ligases can then change the cell fate in the course of disease. Our team published the first crystal structure of the Parkin enzyme, and this insight provides the foundation for our small molecule drug discovery program. FinsnoBio’s proprietary approach has already resulted in discovery of the first small molecule Parkin activators. We are committed to fully leveraging our deep understanding of these fundamentals with the most advanced technologies.
FinsnoBio programs will augment Parkin’s normal repair response, offering a new line of defense in the fight against disease and aging.
We made the discovery. Our goal is to make the cure.™
